Abstract
Background
Long-term pancreatoduodenectomy (PD) survivors have previously reported favorable quality of life (QoL). However, there has been a paucity of studies utilizing pancreas-specific modules for QoL assessment, which may uncover disability that general modules cannot detect.
Methods
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-PAN26 questionnaires were administered to PD survivors who were at least 5 years out of their operations for neoplasms (1998–2011, study cohort) and compared their scores with published preoperative scores of patients with pancreatic cancer (control cohort). The clinical relevance (CR) of differences was scored as small (5–10), moderate (10–20), or large (> 20) based on validated interpretation of clinically important differences.
Results
Of 1266 patients who underwent PD, there were 305 survivors with valid contact information, of whom 248 responded to the questionnaire (response rate 81.3%) and made up the study cohort. The median follow-up was 9.1 years (range 5.1–21.2 years). When compared with the control cohort, patients in the study cohort reported higher pancreatic pain (41.7 ± 17.6 vs. 18.1 ± 20.5, p < 0.001, CR large), sexuality dissatisfaction (63.0 ± 37.5 vs. 35.1 ± 34.3, p < 0.001, CR large), altered bowel habits (37.6 ± 30.6 vs. 20.0 ± 24.5, p < 0.001, CR moderate), and digestive symptoms (26.3 ± 29.5 vs. 18.7 ± 27.8, p = 0.002, CR small) scores. There was a higher prevalence of bloating, indigestion, and flatulence, but lower prevalence of future health worry (71.7% vs. 89.6%, p < 0.001) and limitation in planning activities (30.1% vs. 48.3%, p < 0.001) at 5 years.
Conclusion
While post-PD patients had better long-term global QoL than healthy controls, a more granular, pancreas-specific questionnaire uncovered digestive abnormalities and sexuality dissatisfaction. These data can better inform clinical decision making and provide potential areas for improvement and patient support.
Similar content being viewed by others
References
Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al. 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery. 2012;152(3 Suppl 1):S4–12.
Farrell JJ, Fernandez-del CC. Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology. 2013;144(6):1303–15.
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.
Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment With FOLFIRINOX. Ann Surg. 2019;269(4):733–40.
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–54.
Macedo FI, Ryon E, Maithel SK, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg. 2019;270(3):400–13.
Schniewind B, Bestmann B, Henne-Bruns D, et al. Quality of life after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head. Br J Surg. 2006;93(9):1099–107.
Huang JJ, Yeo CJ, Sohn TA, et al. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg. 2000;231(6):890–8.
Fong ZV, Alvino DM, Castillo CF, et al. Health-related quality of life and functional outcomes in 5-year survivors after pancreaticoduodenectomy. Ann Surg. 2017;266(4):685–92.
Allen CJ, Yakoub D, Macedo FI, et al. Long-term quality of life and gastrointestinal functional outcomes after pancreaticoduodenectomy. Ann Surg. 2018;268(4):657–64.
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer. 1999;35(6):939–41.
Eaton AAKP, Johnson CD, et al. Psychometric validation of the EORTC QLQ-PAN26 pancreatic cancer module for assessing health related quality of life after pancreatic resection. Pancreas. 2017;18(1):19–25.
Eaton AA, Gonen M, Karanicolas P, et al. Health-related quality of life after pancreatectomy: results from a randomized controlled trial. Ann Surg Oncol. 2016;23(7):2137–45.
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.
Balcom JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg. 2001;136(4):391–8.
Winter JM, Cameron JL, Lillemoe KD, et al. (2006) Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg 243(5):673–80; discussion 680-3.
van Rijssen LB, Gerritsen A, Henselmans I, et al. Core set of patient-reported outcomes in pancreatic cancer (COPRAC): an international delphi study among patients and health care providers. Ann Surg. 2019;270(1):158–64.
Heerkens HD, van Berkel L, Tseng DSJ, et al. Long-term health-related quality of life after pancreatic resection for malignancy in patients with and without severe postoperative complications. HPB (Oxford). 2018;20(2):188–95.
Short M, Goldstein D, Halkett G, et al. Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85(1):157–62.
Serrano PE, Herman JM, Griffith KA, et al. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;90(2):270–7.
Arvaniti M, Danias N, Theodosopoulou E, et al. Quality of life variables assessment, before and after pancreatoduodenectomy (PD): prospective study. Glob J Health Sci. 2015;8(6):203–10.
Arvaniti M, Danias N, Igoumenidis M, et al. Comparison of quality of life before and after pancreaticoduodenectomy: a prospective study. Electron Physician. 2018;10(7):7054–62.
Cloyd JM, Tran Cao HS, Petzel MQ, et al. Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Oncol. 2017;115(2):144–50.
Rashid L, Velanovich V. Symptomatic change and gastrointestinal quality of life after pancreatectomy. HPB (Oxford). 2012;14(1):9–13.
Lim PW, Dinh KH, Sullivan M, et al. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB (Oxford). 2016;18(4):360–6.
Gan C, Chen YH, Liu L, et al. Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis. Oncotarget. 2017;8(55):94920–31.
Landers A, Brown H, Strother M. The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study. Palliat Care. 2019;12:1178224218825270.
Puri PM, Watkins AA, Kent TS, et al. Decision-making for the management of cystic lesions of the pancreas: how satisfied are patients with surgery? J Gastrointest Surg. 2018;22(1):88–97.
Eaton AA, Karanicolas P, Johnson CD, et al. Psychometric validation of the EORTC QLQ-PAN26 pancreatic cancer module for assessing health related quality of life after pancreatic resection. J Pancreas. 2017;18(1):19–25.
Acknowledgment
The authors would like to thank the Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research for their funding support for this study.
Funding
Funding was provided by Institute for Pancreatic Cancer Research (Grant No. 0004852948).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fong, Z.V., Sekigami, Y., Qadan, M. et al. Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. Ann Surg Oncol 28, 4216–4224 (2021). https://doi.org/10.1245/s10434-021-09853-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-09853-8